OTCPK:HMGN

Stock Analysis Report

Executive Summary

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Hemagen Diagnostics has significant price volatility in the past 3 months.
  • Hemagen Diagnostics's last earnings update was 2457 days ago.
  • Hemagen Diagnostics is not covered by any analysts.

Similar Companies

Share Price & News

How has Hemagen Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-37.4%

HMGN

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-39.9%

HMGN

9.9%

US Medical Equipment

0.6%

US Market

HMGN underperformed the Medical Equipment industry which returned 9.5% over the past year.

HMGN underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

HMGNIndustryMarket
7 Day-37.4%1.1%-0.6%
30 Day-3.7%0.6%2.2%
90 Day-59.5%2.9%1.1%
1 Year-39.9%-39.9%10.8%9.9%2.9%0.6%
3 Year-13.3%-13.3%70.1%64.9%44.6%35.2%
5 Year-75.7%-75.7%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Hemagen Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hemagen Diagnostics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Hemagen Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Hemagen Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Hemagen Diagnostics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Hemagen Diagnostics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Hemagen Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemagen Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Hemagen Diagnostics performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Hemagen Diagnostics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Hemagen Diagnostics's financial position?


In this section we usually analyse Hemagen Diagnostics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Hemagen Diagnostics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of HMGN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Hemagen Diagnostics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Hemagen Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Hemagen Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Hemagen Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Hemagen Diagnostics has not reported any payouts.

Unable to verify if Hemagen Diagnostics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Hemagen Diagnostics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Hemagen Diagnostics's salary, the management and board of directors tenure and is there insider trading?

15.6yrs

Average board tenure


CEO

William Hales (57yo)

17.5yrs

Tenure

US$192,348

Compensation

Mr. William P. Hales has been the Chief Executive Officer of Hemagen Diagnostics Inc., since March 2002 and has been its President since October 1, 1999. Mr. Hales served as the Principal Financial Officer ...


CEO Compensation Analysis

Insufficient data for William to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Insufficient data for William to compare compensation growth.


Board Age and Tenure

15.6yrs

Average Tenure

72yo

Average Age

The average tenure for the Hemagen Diagnostics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • William Hales (57yo)

    Executive Chairman

    • Tenure: 17.5yrs
    • Compensation: US$192.35k
  • M. Campbell (49yo)

    CFO & COO

    • Tenure: 6.7yrs

Board Members

  • Alan Cohen (93yo)

    Director

    • Tenure: 26.7yrs
    • Compensation: US$10.30k
  • William Hales (57yo)

    Executive Chairman

    • Tenure: 17.5yrs
    • Compensation: US$192.35k
  • Ed Lutz (72yo)

    Director

    • Tenure: 15.6yrs
    • Compensation: US$10.30k

Company Information

Hemagen Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hemagen Diagnostics, Inc.
  • Ticker: HMGN
  • Exchange: OTCPK
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$94.085k
  • Shares outstanding: 15.50m
  • Website: https://www.hemagen.com

Number of Employees


Location

  • Hemagen Diagnostics, Inc.
  • 9033 Red Branch Road
  • Columbia
  • Maryland
  • 21045
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HMGNOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 1993

Biography

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:36
End of Day Share Price2019/09/18 00:00
Earnings2012/09/30
Annual Earnings2012/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.